Boomerang Medical Raises $20 Million Series B to Advance Pivotal Trial of Neuromodulation in Inflammatory Bowel Disease
Trial evaluates neuromodulation’s potential role in ulcerative colitis, the most common form of IBD MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Boomerang Medical, Inc., a women-led bioelectronic medicine company, today announced a $20 million Series B financing co-led by…